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Few newspaper readers can even
have been aware of the need for
double-blind clinical trials of new
drugs, until the recent furore over the
early results of such a trial.
The Independent was explicit in its
front page lead story on 7 April
(“Drug can halve the risk of breast
cancer”). The Guardian was more
cautious (“Drug may halve risk of
breast cancer”). Their common
subject was the release of data from a
trial in the US indicating that
tamoxifen might be highly beneficial
in women who were especially
vulnerable to the disease.
The contrast between these and
other substantial reports in UK
broadsheet newspapers and those in
the tabloids was striking. The Sun, for
example, ignored the news altogether,
while the Mirror gave it three
sentences at the bottom of page 7. So
much for the women readers of these
mass circulation papers.
But this was no ordinary clinical
trial. The US National Cancer
Institute had indeed announced
results (from the National Surgical
Adjuvant Breast and Bowel Project)
which apparently showed a 45%
reduction in the risk of invasive
breast cancer in those of 13,000
women who had been receiving
tamoxifen as a preventative in a
double-blind trial.
The findings, however, were
publicised 14 months before the
original target date because early
results suggested that the drug was
proving highly effective.
Abandoning the trial protocol, and
thus sacrificing some of the
intended clarity in the results, the
organizers had taken the unusual
step of breaking the double-blind.
Hence the prudence of the
Guardian’s headline, and the
cautionary comments from UK
experts embedded in its account and
in most other UK coverage. In
general, however, journalists paid
more attention to the known side-
effects of tamoxifen, rather than to
the possibility that its administration
had simply postponed the
development of breast cancer and
had not prevented it altogether.
It was the potential for toxicity,
too, which persuaded several US
newspapers to use headlines such as
“Cancer breakthrough comes with big
risk” (USA Today) and “Breast cancer
study offers hope but no easy
answers” (Los Angeles Times). Although
most British accounts mentioned
other on-going UK and international
studies (albeit briefly in some cases),
most US writers totally ignored them.
The US papers reflected anxieties
about the side-effects, not the
incompleteness of the results
They continued to do so even after a
press conference called in London by
the Cancer Research Campaign and
the Imperial Cancer Research Fund,
which received extensive coverage in
the British press on 8 April. In
contrast to expert comments
published the previous day (“This is
very, very encouraging”, Dr Trevor
Powles; “We are delighted”, Dr John
Toy), the tone became extremely
sceptical.
“Doctors accuse US of wrecking
cancer drug test … Researchers are
angry that early announcement of
results ruins other trials,” said the
Times. “US breast cancer claims
denounced … It will take years to be
sure about new drug,” said the
Guardian.
The Guardian’s coverage at this
stage was superb. In addition to a
news item, health correspondent
Sarah Boseley contributed a
comprehensive analysis, two thirds
of a page in length, accompanied by
diagrams and references to source
material. This was a model feature
of the type often required by the
public but seldom provided by the
media, and which is essential to
explain such a complex issue fully.
The Times adopted a similar
approach, with a collation of four
pieces on different aspects of the
story. One was an admirably succinct
summary by science editor Nigel
Hawkes of the problems created by
the premature termination of the US
study, focusing particularly on the
important questions that will now
never be answered.
With the conspicuous exception
of the New York Times, caveats
concerning the “wrecked” trial were
largely absent from US coverage.
Reports were tempered, certainly, by
warnings of side-effects, and in some
instances by careful observations on
the potential application of genetic
tests to identify high-risk women.
But few reporters highlighted the
inherent uncertainties in conclusions
from a study abandoned long before
the end of the time originally
deemed necessary for unambiguous
results. And the word “breakthrough”
was much used.
Were UK readers, on the other
hand, likely to be confused by the
spectacle of one seemingly
authoritative group of experts
repudiating research findings
reported by another? After all, this
was not a clash of opinion as to what
causes obesity, autism or depression,
but a disagreement over the very
foundations of scientific method.
The question is valid.
Nevertheless, Britain’s newspaper
readers probably learned more about
the theoretical and practical dilemma
inherent in double-blind studies than
US readers did from their country’s
style of reportage. As the Los Angeles
Times observed, this was a story with
no easy answers. Yet the wider
perspective adopted by most UK
journalists did much to aid
understanding.
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